Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Byetta Prescribers for Diabetes (US)

Articles with lock require a subscription to GLG News | Request a free trial
February 11, 2008
Right data, wrong interpretation?
Analysis of: Diabetes Study Partially Halted After Deaths | www.nytimes.com
Author: GLG Expert Contributor
That more people died in the "tight" control group is true, but was it tight control that was responsible or could it have been the means by which it was controlled?  It was not rosigitazone (Avandia) or hypoglycemia responsible for the deaths, according to the articles (the scientific article...
February 11, 2008
Premature declararation without in depth analysis.
Analysis of: Diabetes Study Partially Halted After Deaths | www.nytimes.com
Author: GLG Expert Contributor
I beleive that this  announcement is premature and more about being too preacutious in the present litigenous environment. Sevral variable factors may responsible for the outcomes and not just the strict glycemic control.
Joseph BassFebruary 8, 2008
Warning on A1C Targets and Diabetes Death in ACCORD Trial
Analysis of: Hault of ACCORD Study Intensive Treatment Arm | www.nhlbi.nih.gov
Author: Joseph Bass, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare
Increased death from intensive A1C lowering in diabetic subjects raises new concerns about diabetes therapy, insulin use in combination with oral agents, and clinical biomarkers of disease complications.
Joseph BassFebruary 5, 2008
Predicting Winners in Oral Diabetes Competition: Galvus, Alogliptin & Januvia
Analysis of: Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Author: Joseph Bass, Division Head of Endocrinology and Metabolism, Evanston Northwestern Healthcare
Oral therapies improve complianceEU approval of Galvus does not erase US doubts
February 4, 2008
Galvus Receives Approval, But A Larger Battle Remains
Analysis of: Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com
Author: GLG Expert Contributor
Galvus receives European approval, but has significant barriers for prescribing. This places Galvus significantly behind Januvia as a diabetes treatment option
February 4, 2008
Stay Alert for Registration Trial Results
Analysis of: Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R)) | www.pipelinereview.com
Author: GLG Expert Contributor
After the many false hopes raised using surrogate markers, we certainly want to wait for definitive end-point trial results involving fracture rate and possible long-term side effects.  However the 40% greater increase in BMD compared to the standard of bisphosphonate therapy is quite exciting. ...
Carlos DujovneJanuary 23, 2008
Dying patient denied access to experimental drugs is contrary to common sense and discovery of new treatments.
Analysis of: No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
One, twenty years ago I was the chairman of the government affairs committee of the American Society for Clinical Pharmacology and Therapeutics; under that role my committee was successful lobbying for approval new investigational drugs for possible treatment of AIDS. We were successful in getting the...
January 18, 2008
I couldn't agree more
Analysis of: WellPoint patients to review doctors online | www.healthcarefinancenews.com
Author: GLG Expert Contributor
Insurance company data is primitive and flawed. Any entity that can manage this data well in the future will be extremely profitable.
January 18, 2008
Outsourcing of compassionate use of drugs?
Analysis of: No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com
Author: Dan Streja, Clinical Professor of Medicine, University of California, Los Angeles
The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...
Carlos DujovneJanuary 17, 2008
Merck Developement of Anacetrapib not as Risky as it may appear!
Analysis of: Merck & Co.: Engaging in Risky Business? | www.pharmaweek.com
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
My expertise in the clinical research of Torcetrapib and reports presented at the latest American College of Cardiology meetings made me conclude that the failure of  Torcetrapib in rendering clinical benefits were related to intrinsic problems of the drug which effected the nature of the HDL which...

Previous Page : 1 2 3 4 5 6 7 8 9 Next21 to 30 of 90

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747